Charles River Laboratories International Inc CRL

Morningstar Rating
Add To Portfolio
|%
Chart Data Not Available
  • Last Close
  • Sector
  • Industry
  • Investment Style
    Small Core
  • Market Cap
  • Forward Div Yield
  • Trailing Div Yield
  • Price/Sales
    2.56
  • Price/Book
    2.72
  • Beta (5-Year)
    1.48
  • Consensus Forward P/E
    20.24
  • Trailing 12-mo Rev

Morningstar's Analysis

Valuation May 05, 2025
Currency in USD
Is it the right time to buy or sell?
Fair ValueLearn Moreplay
1-Star Price
Premium
Economic Moat
Premium
5-Star Price
Premium
Capital Allocation
Premium
Charles River Earnings: Stock Soars as Elliott Investment Management Launches Strategic Review
Author Photo
Rachel Elfman
Equity Analyst
Analyst Note | by Rachel Elfman Updated May 08, 2025

Narrow-moat Charles River Laboratories announced an agreement with Elliott Investment Management to add four new directors to its board and enhance value creation through a strategic review to optimize the company’s performance and drive efficiencies. Investors were spooked last month by the US Food and Drug Administration’s announcement to reduce animal testing for preclinical safety assessments. However, management provided more details on how it plans to advance hybrid study designs by complementing traditional animal studies with technologies such as artificial intelligence, and it will continue to expand its nonanimal platforms to address evolving regulations. Shares soared almost 19% after the earnings update, as investor confidence increased in the firm’s long-term prospects.

Business Strategy and Outlook | by Rachel Elfman Updated Feb 19, 2025

Animal research models have been the foundation of Charles River Laboratories' business since 1947, and the company has expanded to provide solutions encompassing research models and related services, drug discovery, preclinical testing, and manufacturing support. It services nearly all top and mid-tier biopharma players.

Charles River focuses on

Morningstar Fair Value Estimate
The Morningstar Fair Value Estimate guides investors to the long-term, intrinsic value of a stock, helping them see beyond the present market price.

Show me how fair value is derived (00:41)

Morningstar calculates the fair value estimate of a company based on a projection of how much cash the company will generate in the future. Morningstar analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. The analyst discounts future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

The Morningstar Fair Value Estimate is a projection/opinion and not a statement of fact. If Morningstar's base-case assumptions are true the market price will converge on Morningstar's fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in the future and is no indication of future performance.

Morningstar Equity Research Methodology

Price vs. Fair Value

 
Price/Fair Value
Total Return %
Index Total Return %
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 YTD
26.32 -5.22 43.65 3.41 34.97 63.56 50.80 -42.17 8.49 -21.91 -22.42
0.69 12.44 21.47 -5.05 31.22 20.90 25.78 -19.43 26.44 24.09 1.93

Related

Morningstar Research
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility